http://mhh5zxjz.cn/en/2024/11/11/officially-approved-anfangning-kras-g12c-inhibitor-garsorasib-receives-market-authorization-from-the-national-medical-products-administration-nmpa-of-china/2024-12-02T23:01:22+08:00http://mhh5zxjz.cn/en/2024/09/10/2024-wclc-latest-progress-of-garsorasib-d-1553-in-treating-kras-g12c-mutant-lung-cancer-phase-2-study-updates/2024-11-28T11:18:55+08:00http://mhh5zxjz.cn/en/2024/06/13/garsorasib-d-1553-new-indication-added-to-breakthrough-therapy-designation-program/2024-11-28T11:18:59+08:00http://mhh5zxjz.cn/en/2024/06/11/garsorasib-d-1553-phase-ii-study-results-for-lung-cancer-published-in-prestigious-international-journal/2024-11-28T11:19:03+08:00http://mhh5zxjz.cn/en/2024/03/13/inventisbio-to-present-phase-ii-clinical-data-of-garsorasib-d-1553-for-lung-cancer-at-the-2024-aacr-annual-meeting/2024-11-28T11:19:07+08:00http://mhh5zxjz.cn/en/2024/12/03/elementor-6666/2025-03-25T14:02:04+08:00